Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder

Abstract

Objectives: To evaluate the efficacy and tolerability of tolterodine extended release (ER) in men and women with overactive bladder (OAB).

Methods: We analyzed data from two 12-wk, placebo-controlled trials of tolterodine ER (4mg QD). Patients completed 7-d bladder diaries and rated the urgency sensation associated with each micturition on a 5-point urgency rating scale. Micturitions were categorized by urgency rating: total (1-5), non-OAB (1-2), OAB (3-5), or severe OAB (4-5). Changes in micturitions during 24-h, daytime, and nocturnal intervals were assessed.

Results: At baseline, 73% (547 of 745) of men and 57% (539 of 953) of women were continent. By week 12, tolterodine ER (n=848) reduced OAB and severe OAB micturitions during 24-h, daytime, and nocturnal intervals in both sexes compared with placebo (n=850). Adverse event rates were low and similar across treatment and gender.

Conclusions: In men and women with OAB, tolterodine ER reduced OAB and severe OAB micturitions, and was well tolerated.